Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

I downgrade Pfizer to 'Strong Sell' as its high dividend yield fails to offset persistent share price weakness and lack of ...

While it no longer generates the sales it once did, Pfizer's coronavirus lineup remains critical to its results. The past ...

European Commission approves Adcetris, Takeda & Pfizer's antibody-drug combo, for frontline Hodgkin lymphoma. Read more here.

According to Pfizer Inc., only two Depo-Provera lawsuits had been filed in the Philadelphia Court of Common Pleas as of the ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer ...

Pfizer (NYSE:PFE) recently ended its strategic collaboration with Acepodia and is facing legal challenges related to ...

South Korea's top court clears SK Bioscience’s vaccine of patent violation, unlocking export potential and global market ...

The data showed a surprisingly compelling overall survival (OS) benefit. TheBraftovi combination regimen received Food and ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Trump's trade war has created a carve-out bonanza for industries with political connections and big lobbying budgets.

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...